Thiolated ?-cyclodextrin modified iron oxide nanoparticles for effective targeted cancer therapy

dc.contributor.authorNayak, Jyotsnamayee
dc.contributor.authorPrajapati, Kumari Sunita
dc.contributor.authorKumar, Shashank
dc.contributor.authorVashistha, Vinod Kumar
dc.contributor.authorSahoo, Suban K.
dc.contributor.authorKumar, Rajender
dc.date.accessioned2024-01-16T14:23:17Z
dc.date.accessioned2024-08-13T10:34:13Z
dc.date.available2024-01-16T14:23:17Z
dc.date.available2024-08-13T10:34:13Z
dc.date.issued2022-10-13T00:00:00
dc.description.abstractInspired by the mitochondria iron-sulfur protein, direct functionalization of thiolated ?-cyclodextrin (?-CD-SH) on iron oxide nanoparticles (IONPs) through Fe-S bond was done. The resulting system had an average size of 14 nm with an ellipsoidal shape. The X-Ray photoelectron spectroscopy (XPS) confirmed the formation of the Fe-S bond. Doxorubicin (DOX) was chosen as a model drug, about 12.45 �M/mg entrapped in ?-CD-SH coated IONPs (T?CD-IONPs). The hybrid nanocarrier possessed high stability and drug loading efficiency. The invitro release data revealed an overall sustainable release profile without initial bust. The Higuchi kinetic model best fits the release mechanism, based on diffusion action in dosages proportional to the square root of time. The surface coating and particle size have a crucial role in the cellular responses and effective toxic mechanisms. The cellular internalization of drug-loaded nanoparticles (NPs) into the breast cancer cell line MCF-07 was done using MTT assay and confocal imaging. The prepared system shows high performance with an IC50 value at 67 nM of nanoparticle concentration. The prepared nanoparticles are promising candidates for the effective targeted delivery of hydrophobic drugs with enhanced theragnostic activity. � 2022 Elsevier Ltden_US
dc.identifier.doi10.1016/j.mtcomm.2022.104644
dc.identifier.issn23524928
dc.identifier.urihttps://doi.org/10.1016/j.mtcomm.2022.104644
dc.identifier.urihttps://kr.cup.edu.in/handle/32116/2896
dc.language.isoen_USen_US
dc.publisherElsevier Ltden_US
dc.subjectCancer therapyen_US
dc.subjectDoxorubicinen_US
dc.subjectIron oxide nanoparticlesen_US
dc.subjectMitochondrial Fe-S proteinen_US
dc.subjectTargeted therapyen_US
dc.subjectThiolated ?-cyclodextrinen_US
dc.titleThiolated ?-cyclodextrin modified iron oxide nanoparticles for effective targeted cancer therapyen_US
dc.title.journalMaterials Today Communicationsen_US
dc.typeArticleen_US
dc.type.accesstypeClosed Accessen_US

Files